keyword
MENU ▼
Read by QxMD icon Read
search

phase III carcinoma

keyword
https://www.readbyqxmd.com/read/28068178/cetuximab-plus-chemoradiotherapy-in-immunocompetent-patients-with-anal-carcinoma-a-phase-ii-eastern-cooperative-oncology-group-american-college-of-radiology-imaging-network-cancer-research-group-trial-e3205
#1
Madhur K Garg, Fengmin Zhao, Joseph A Sparano, Joel Palefsky, Richard Whittington, Edith P Mitchell, Mary F Mulcahy, Karin I Armstrong, Nassim H Nabbout, Shalom Kalnicki, Bassel F El-Rayes, Adedayo A Onitilo, Daniel J Moriarty, Thomas J Fitzgerald, Al B Benson
Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection. Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal squamous cell carcinoma, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC. Methods Sixty-one patients with stage I to III SCCAC received CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor and regional lymph nodes (45 to 54 Gy) plus eight once-weekly doses of concurrent cetuximab...
January 9, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28067062/developments-in-pharmacotherapy-for-treating-metastatic-non-small-cell-lung-cancer
#2
Antonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, Assunta Sgambato, Francesca Casaluce, Giovanni Palazzolo, Paolo Maione, Cesare Gridelli
Most patients with non-small cell lung (NSCLC), including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis and systemic therapy is the standard-of-care. About 20% of Caucasian patients are affected by an oncogene-addicted advanced NSCLC for which correspondent inhibitors are available. Areas covered: The main state-of-the-art synthetic anticancer drugs in the groups of chemotherapeutics, epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors for NSCLC treatment, are reviewed and discussed from phase III randomized practice-changing trials onwards...
January 8, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28046847/su-g-iep1-05-diffusion-kurtosis-imaging-for-oropharyngeal-cancer-detection
#3
Y Ding, A Mohamed, J Ma, S Frank, J Wang, C Fuller
PURPOSE: Diffusion kurtosis imaging (DKI) is an emerging diffusion MRI technique in cancer diagnosis applications. The objective of this study is to compare DKI with conventional diffusion weighted imaging (DWI) for diagnosis of head and neck cancer. METHODS: Five male patients with histologically documented phase II/III squamous cell carcinoma of the oropharynx were included in this study. DKI (with 6 b-values of 0-2000 s/mm2) and conventional DWI data were acquired at a 3...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28045619/impact-of-viral-status-on-survival-in-patients-receiving-sorafenib-for-advanced-hepatocellular-cancer-a-meta-analysis-of-randomized-phase-iii-trials
#4
Richard Jackson, Eftychia-Eirini Psarelli, Sarah Berhane, Harun Khan, Philip Johnson
Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. To address this, we undertook an individual patient data meta-analysis of three large prospective randomized trials in which sorafenib was the control arm. Methods Of a total of 3,256 patients, 1,643 (50%) who received sorafenib were available...
January 3, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28043166/pharmacokinetic-drug-evaluation-of-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma
#5
Rutveej Patel, Megan Bock, Charles F Polotti, Sammy Elsamra
Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who progress during or after initial chemotherapy regimens. Current regimens offer low response rates with high toxicities. The advent of immune checkpoint inhibitors may represent a new opportunity for effective management of these patients. Areas covered: Atezolizumab is an engineered humanized monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. It is administered intravenously and is given every 3 weeks as long as there is no evidence of tumor progression...
January 3, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28042235/novel-implications-in-the-treatment-of-hepatocellular-carcinoma
#6
REVIEW
Jan Best, Clemens Schotten, Jens M Theysohn, Axel Wetter, Stefan Müller, Sonia Radünz, Maren Schulze, Ali Canbay, Alexander Dechêne, Guido Gerken
Worldwide hepatocellular carcinoma remains one of the leading causes of cancer-related death, associated with a poor prognosis due to late diagnosis in the majority of cases. Physicians at care are frequently confronted with patients who are ineligible for curative treatment such as liver resection, transplantation or radiofrequency ablation. Besides established palliative locoregional therapies, such as ablation or chemoembolization, new treatment options, such as microwave ablation, drug-eluting bead transarterial chemoembolization or selective internal radiation therapy, are emerging; however, data from randomized controlled trials are still lacking...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28040660/quality-of-life-and-swallowing-with-standard-chemoradiotherapy-versus-accelerated-radiotherapy-and-panitumumab-in-locoregionally-advanced-carcinoma-of-the-head-and-neck-a-phase-iii-randomised-trial-from-the-canadian-cancer-trials-group-hn-6
#7
Jolie Ringash, John N Waldron, Lillian L Siu, Rosemary Martino, Eric Winquist, Jim R Wright, Abdenour Nabid, John H Hay, Alex Hammond, Khalil Sultanem, Sebastien Hotte, Carson Leong, Ali Abdel Halim El-Gayed, Farah Naz, Kevin Ramchandar, Timothy E Owen, Alexander Montenegro, Brian O'Sullivan, Bingshu E Chen, Wendy R Parulekar
AIM: To compare quality of life (QOL) between standard (SFX) chemoradiotherapy (arm A) and altered fractionation radiotherapy (AFX) with panitumumab (PMab; arm B). METHODS: Patients with T any N + M0 or T3-4N0M0 squamous cell head-neck carcinoma were randomised to SFX (70 Gy/35/7 wks) plus cisplatin (100 mg/m(2) IV × 3) versus AFX (70 Gy/35/6 wks) plus PMab (9 mg/kg IV × 3). QOL was collected at baseline, end of radiation therapy (RT) and 2, 4, 6, 12, 24 and 36 months post-RT using the Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N), MD Anderson Dysphagia Index (MDADI) and SWAL-QOL...
December 29, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28029303/e1308-phase-ii-trial-of-induction-chemotherapy-followed-by-reduced-dose-radiation-and-weekly-cetuximab-in-patients-with-hpv-associated-resectable-squamous-cell-carcinoma-of-the-oropharynx-ecog-acrin-cancer-research-group
#8
Shanthi Marur, Shuli Li, Anthony J Cmelak, Maura L Gillison, Weiqiang J Zhao, Robert L Ferris, William H Westra, Jill Gilbert, Julie E Bauman, Lynne I Wagner, David R Trevarthen, Jahagirdar Balkrishna, Barbara A Murphy, Nishant Agrawal, A Dimitrios Colevas, Christine H Chung, Barbara Burtness
Purpose Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is treatment-responsive. Definitive chemoradiation results in high cure rates but causes long-term toxicity and may represent overtreatment of some patients. This phase II trial evaluated whether complete clinical response (cCR) to induction chemotherapy (IC) could select patients with HPV-associated OPSCC for reduced radiation dose as a means of sparing late sequelae. Methods Patients with HPV16 and/or p16-positive, stage III-IV OPSCC received three cycles of IC with cisplatin, paclitaxel, and cetuximab...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28028637/phase-i-clinical-trial-of-olprinone-in-liver-surgery
#9
Hiroaki Fuji, Etsuro Hatano, Kohta Iguchi, Kenya Yamanaka, Tomoaki Yoh, Yoshinobu Ikeno, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Shiro Tanaka, Hisanari Ishii, Mariko Kobayashi, Kazuyuki Ueno, Shinji Uemoto
PURPOSE: Post-hepatectomy liver failure is one of the most serious complications liver surgeons must overcome. We previously examined olprinone, a selective phosphodiesterase III inhibitor, and demonstrated its hepatoprotective effects in rats and pigs. We herein report the results of a phase I clinical trial of olprinone in liver surgery (UMIN000004975). METHODS: Twenty-three patients who underwent hepatectomy between 2011 and 2015 were prospectively registered...
December 27, 2016: Surgery Today
https://www.readbyqxmd.com/read/28011050/could-the-addition-of-cetuximab-to-conventional-radiation-therapy-improve-organ-preservation-in-those-patients-with-locally-advanced-larynx-cancer-who-respond-to-induction-chemotherapy-an-organ-preservation-spanish-head-and-neck-cancer-cooperative-group-phase
#10
Ricard Mesía, Jose A Garcia-Saenz, Alicia Lozano, Miguel Pastor, Juan J Grau, Javier Martínez-Trufero, Julio Lambeaz, Joaquina Martínez-Galán, Jose R Mel, Belen González, Silvia Vázquez, Manel Mañós, Miren Taberna, Beatriz Cirauqui, Elvira Del Barco, Esther Casado, Jordi Rubió-Casadevall, Angles Rodríguez-Jaráiz, Juan J Cruz
PURPOSE: To evaluate the efficacy and safety of induction chemotherapy (IC) followed by bioradiotherapy (BRT) to achieve functional larynx preservation in the setting of locally advanced head and neck tumors. METHODS AND MATERIALS: This was a phase 2, open-label, multicenter study of patients with stage III and IVA laryngeal carcinoma who were candidates for total laryngectomy. The primary endpoint was the rate of survival with functional larynx (SFL) at 3 years, with a critical value to consider the study positive of SFL >59%...
November 17, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28008780/carnosine-inhibits-the-proliferation-of-human-cervical-gland-carcinoma-cells-through-inhibiting-both-mitochondrial-bioenergetics-and-glycolysis-pathways-and-retarding-cell-cycle-progression
#11
Yun Bao, Saidan Ding, Jiaoyan Cheng, Yuan Liu, Bingyu Wang, Huijuan Xu, Yao Shen, Jianxin Lyu
Carnosine has been demonstrated to play an antitumorigenic role in certain types of cancer. However, its underlying mechanism is unclear. In this study, the roles of carnosine in cell proliferation and its underlying mechanism were investigated in the cultured human cervical gland carcinoma cells HeLa and cervical squamous carcinoma cells SiHa. The results showed that carnosine exerted a significant inhibitory effect on the proliferation of HeLa cells, whereas its inhibitory action on the proliferation of SiHa cells was much weaker...
December 1, 2016: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/28001301/tumor-response-to-neoadjuvant-chemotherapy-predicts-long-term-survival-outcomes-in-patients-with-locoregionally-advanced-nasopharyngeal-carcinoma-a-secondary-analysis-of-a-randomized-phase-3-clinical-trial
#12
Hao Peng, Lei Chen, Wen-Fei Li, Rui Guo, Yan-Ping Mao, Yuan Zhang, Ying Guo, Ying Sun, Jun Ma
BACKGROUND: Tumor response to neoadjuvant chemotherapy using the regimen of cisplatin and 5-fluorouracil could define high-risk patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, the regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) appears to be more effective than the regimen of cisplatin and 5-fluorouracil. Therefore, one needs to redefine the high-risk subpopulation of patients receiving neoadjuvant chemotherapy with TPF. METHODS: A total of 231 patients from a randomized phase 3 trial with American Joint Committee on Cancer/International Union Against Cancer stage III to stage IVB NPC (except T3-T4N0 disease) who were receiving treatment with the TPF regimen were enrolled...
December 21, 2016: Cancer
https://www.readbyqxmd.com/read/27992479/octreotide-lar-and-prednisone-as-neoadjuvant-treatment-in-patients-with-primary-or-locally-recurrent-unresectable-thymic-tumors-a-phase-ii-study
#13
Lukas Kirzinger, Sandra Boy, Jörg Marienhagen, Gerhard Schuierer, Reiner Neu, Michael Ried, Hans-Stefan Hofmann, Karsten Wiebe, Philipp Ströbel, Christoph May, Julia Kleylein-Sohn, Claudia Baierlein, Ulrich Bogdahn, Alexander Marx, Berthold Schalke
Therapeutic options to cure advanced, recurrent, and unresectable thymomas are limited. The most important factor for long-term survival of thymoma patients is complete resection (R0) of the tumor. We therefore evaluated the response to and the induction of resectability of primarily or locally recurrent unresectable thymomas and thymic carcinomas by octreotide Long-Acting Release (LAR) plus prednisone therapy in patients with positive octreotide scans. In this open label, single-arm phase II study, 17 patients with thymomas considered unresectable or locally recurrent thymoma (n = 15) and thymic carcinoma (n = 2) at Masaoka stage III were enrolled...
2016: PloS One
https://www.readbyqxmd.com/read/27992367/management-of-salivary-gland-carcinomas-a-review
#14
REVIEW
Xiaoli Wang, Yijun Luo, Minghuan Li, Hongjiang Yan, Mingping Sun, Tingyong Fan
Salivary gland carcinomas are a heterogeneous group of tumors with many histological subtypes which occur in both major and minor salivary glands. However, they have a relatively low of incidence. Their rarity limits study size and the ability to perform phase III trials. Therefore, to date, the entire management is usually varied. Certain published studies have paid more attention to the systemic therapy in the management of metastatic or locally recurrent salivary gland cancer, while little effort has been made to study the entire management for this lesions...
December 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27943254/minimally-invasive-surgery-versus-radiotherapy-chemoradiotherapy-for-small-volume-primary-oropharyngeal-carcinoma
#15
REVIEW
James Howard, Liam Masterson, Raghav C Dwivedi, Faruque Riffat, Richard Benson, Sarah Jefferies, Piyush Jani, James R Tysome, Chris Nutting
BACKGROUND: More than 400,000 cases of oropharyngeal squamous cell carcinoma (OPSCC) are diagnosed each year worldwide and the incidence is rising, partly as a result of human papillomavirus. Human papillomavirus-associated OPSCC affects younger patients and often presents at a higher stage; however, it is associated with a better prognosis.Until recently, first-line management of OPSCC involved chemoradiotherapy, as research had demonstrated comparable survival outcomes when compared with open surgery, with significantly decreased morbidity...
December 11, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27941701/influence-of-tyrosine-kinase-inhibitors-on-hypertension-and-nephrotoxicity-in-metastatic-renal-cell-cancer-patients
#16
REVIEW
Aleksandra Semeniuk-Wojtaś, Arkadiusz Lubas, Rafał Stec, Cezary Szczylik, Stanisław Niemczyk
Renal cell carcinoma (RCC) is one of the most common kidney malignancies. An upgraded comprehension of the molecular biology implicated in the development of cancer has stimulated an increase in research and development of innovative antitumor therapies. The aim of the study was to analyze the medical literature for hypertension and renal toxicities as the adverse events of the vascular endothelial growth factor (VEGF) signaling pathway inhibitor (anti-VEGF) therapy. Relevant studies were identified in PubMed and ClinicalTrials...
December 9, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27937092/cetuximab-plus-chemoradiotherapy-for-hiv-associated-anal-carcinoma-a-phase-ii-aids-malignancy-consortium-trial
#17
Joseph A Sparano, Jeannette Y Lee, Joel Palefsky, David H Henry, William Wachsman, Lakshmi Rajdev, David Aboulafia, Lee Ratner, Thomas J Fitzgerald, Lisa Kachnic, Ronald Mitsuyasu
Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection. Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal SCC, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC. Methods Forty-five patients with stage I to III SCCAC and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor and regional lymph nodes plus eight once-weekly doses of concurrent cetuximab and two cycles of cisplatin and fluorouracil...
December 12, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27913776/necitumumab-for-the-treatment-of-squamous-cell-non-small-cell-lung-cancer
#18
Jessica K Brinkmeyer, Donald C Moore
Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza™, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer...
December 2, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27906472/long-term-clinical-impact-and-cost-effectiveness-of-obeticholic-acid-for-the-treatment-of-primary-biliary-cholangitis
#19
Sumeyye Samur, Matthew Klebanoff, Reiner Banken, Daniel S Pratt, Rick Chapman, Daniel A Ollendorf, Anne M Loos, Kathleen Corey, Chin Hur, Jagpreet Chhatwal
: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that mainly affects middle-aged women. Obeticholic acid (OCA), which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated positive effects on biochemical markers of liver function. Our objective was to evaluate the long-term clinical impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA...
November 7, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#20
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
keyword
keyword
86070
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"